Lexaria Bioscience Corp. Files 8-K with Material Agreement

TL;DR

Lexaria Bioscience filed an 8-K on Feb 5, 2025, reporting a material definitive agreement and financial statements.

AI Summary

On February 5, 2025, Lexaria Bioscience Corp. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits, indicating significant corporate activity. The company, incorporated in Nevada, is involved in the Pharmaceutical Preparations industry.

Why It Matters

This 8-K filing signals a significant corporate event for Lexaria Bioscience Corp., potentially impacting its business operations and investor outlook.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of the agreement are not detailed in this summary.

Key Numbers

• 001-39874 — SEC File Number (Identifies the company's filing with the SEC)
• 20-2000871 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Lexaria Bioscience Corp. (company) — Registrant
• February 5, 2025 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 2834 (industry_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
• $5,000,000 — ssue and sell, from time to time, up to $5,000,000 in aggregate principal amount of shares
• $20,000,000 — rovided for the issue and sale of up to $20,000,000 in aggregate principal amount of shares

Filing Documents

• lxrp_8k.htm (8-K) — 32KB
• lxrp_ex51.htm (EX-5.1) — 13KB
• lxrp_ex101.htm (EX-10.1) — 11KB
• lxrp_ex51img2.jpg (GRAPHIC) — 6KB
• lxrp_ex51img1.jpg (GRAPHIC) — 6KB
• 0001640334-25-000192.txt ( ) — 219KB
• lxrp-20250205.xsd (EX-101.SCH) — 6KB
• lxrp-20250205_lab.xml (EX-101.LAB) — 16KB
• lxrp-20250205_cal.xml (EX-101.CAL) — 1KB
• lxrp-20250205_pre.xml (EX-101.PRE) — 12KB
• lxrp-20250205_def.xml (EX-101.DEF) — 4KB
• lxrp_8k_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On February 5, 2025, Lexaria Bioscience Corp. (the "Company") and JonesTrading Institutional Services LLC (the "Agent") entered into Amendment No. 1 (the "Amendment") to the Capital on Demand Sales Agreement between the parties originally entered into on August 21, 2024 (the "Original Agreement" and, as amended by the Amendment, the "Sales Agreement"). The Amendment amends the Original Agreement to (i) amend the defined term "Registration Statement" to refer to the Company's current active registration statement on Form S-3 (333-284407) and (ii) provide that the Company may issue and sell, from time to time, up to $5,000,000 in aggregate principal amount of shares (the "Shares") of the Company's common stock through or to the Agent, as the Company's sales agent or principal. The Original Agreement had provided for the issue and sale of up to $20,000,000 in aggregate principal amount of shares. Any Shares to be offered and sold under the Sales Agreement will be issued and sold by methods deemed to be an "at-the-market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Act"), or in negotiated transactions, if authorized by the Company.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 5.1 Opinion of Sichenzia Ross Ference Carmel LLP 10.1 Amendment to the Capital on Demand Sales Agreement, dated as of February 5, 2025, by and between Lexaria Bioscience Corp. and JonesTrading Institutional Services LLC 23.1 Consent of Sichenzia Ross Ference Carmel LLP (contained in the opinion filed as Exhibit 5.1 hereto) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 5, 2025 LEXARIA BIOSCIENCE CORP. /s/ Richard Christopher Name: Richard Christopher Title: Chief Executive Officer 4